Compass Pathways shares surged over 30% on Tuesday after the company announced positive results from COMP006, the second of two pivotal Phase 3 trials for its psilocybin-based therapy COMP360 in treatment-resistant depression.

#CMPS #CMPSStock #COMP360 #CompassPathways #Psychedelics

Compass Pathways shares surged over 30% on Tuesday after the company announced positive results from COMP006, the second of two pivotal Phase 3 trials for its psilocybin-based therapy COMP360 in treatment-resistant depression.

#CMPS #CMPSStock #COMP360 #CompassPathways #Psychedelics

Compass Pathways announced that the US FDA has accepted its Investigational New Drug application for COMP360, a psilocybin-based therapy for PTSD.

#CMPS #Psilocybin #PTSD #CMPSStock #CMPSNews #CompassPathways #CompassPathwaysStock #CompassPathwaysNews #ClinicalTrial #COMP360 #FDAApproval
$CMPS